Information about school immunization requirements and data

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season.

This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age).
CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here.
• Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors.
• These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US)
• Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*.
• People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.
* DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

Characteristics of individuals receiving a booster vaccination.

Note: As of 1/22/25, this dataset is no longer updated. This dataset reports the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. Currently, three COVID-19 vaccines have been authorized for emergency use by the FDA and approved by New York State's independent Clinical Advisory Task Force: one that was developed by Pfizer and BioNTech, a second that was developed by Moderna and a third that was developed by Janssen/Johnson & Johnson. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the state to serve as points of distribution. This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR).

NYSIIS and CIR are confidential, secure, web-based systems that collect and maintain immunization information in one consolidated record for persons of all ages in NYS governed by Public Health Law 2168. Health care providers are required, by law, to enter all vaccines administered to children up to age 19. Immunizations administered to adults 19 and older may be reported with consent. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

Vaccination data by age is based on address data reported to NYSIIS and NYC CIR by the providers administering vaccines. Age is calculated by subtracting the dob from the date of vaccination. Note that COVID-19 vaccine availability greatly expanded for the different age groups over the period of time this dataset covers. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for age group statistics. This dataset is updated weekly.

Characteristics of individuals completing the primary series.

Note: As of November 10, 2023, this dataset has been archived. For the current version of this data, please visit: https://health.data.ny.gov/d/gikn-znjh

This dataset reports daily on the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the State to serve as points of distribution.

This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR). County-level vaccination data is based on data reported to NYSIIS and NYC CIR by the providers administering vaccines. Residency is self-reported by the individual being vaccinated. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for county-level statistics. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

COVID-19 vaccination data in Israel processed to show vaccination by age over time. These datasets are derived from publicly available Ministry of Health data, but processed for analytics about uptake in different age groups over time. They cover the mass vaccination campaign for COVID-19 until August 2021. The campaign consisted of the administration of multiple doses of the Pfizer vaccine.

The Mobile Vaccination Workstation market is experiencing robust growth, driven by the increasing need for efficient and accessible vaccination services, particularly in remote areas and during public health emergencies. The market's expansion is fueled by several factors, including rising vaccination rates globally, advancements in vaccine technology requiring specialized storage and handling, and a growing emphasis on improving healthcare infrastructure. Technological innovations within mobile workstations, such as integrated refrigeration systems, electronic health record (EHR) integration, and improved ergonomics, are further enhancing market appeal. The market is segmented by workstation type (refrigerated, non-refrigerated), application (mass vaccination campaigns, rural healthcare, mobile clinics), and end-user (government agencies, private healthcare providers). Competition is moderately intense, with established players like Capsa Healthcare and Ergotron alongside emerging innovative companies like Enovate Medical vying for market share. While the initial investment cost of these workstations can be a restraint, the long-term cost savings from increased efficiency and improved vaccination rates outweigh this factor. We estimate the market size in 2025 to be $500 million, growing at a compound annual growth rate (CAGR) of 15% through 2033. This projection considers the aforementioned drivers and trends while acknowledging potential market saturation in specific regions and the need for ongoing technological advancements to maintain growth. The geographical distribution of the market shows strong growth across North America and Europe, driven by well-established healthcare infrastructure and high vaccination rates. However, significant opportunities exist in developing economies where access to vaccination is limited. As governmental initiatives to improve healthcare access expand, and as the focus shifts to sustainable and efficient vaccination strategies, particularly in the aftermath of the global pandemic, the demand for mobile vaccination workstations will continue to rise. Market players are strategically focusing on improving usability, incorporating advanced technology, and strengthening distribution channels to cater to the diverse needs of various end-users. This focus on innovation, along with sustained public health initiatives, will ensure the long-term viability and growth of this crucial market segment.

BackgroundAmidst growing concern about an increased risk of Guillain–Barré syndrome (GBS) following COVID-19 vaccination, clinical and electrodiagnostic features have not been fully characterized.MethodsWe retrospectively reviewed medical records of the patients diagnosed with GBS and its variants following COVID-19 vaccination at four referral hospitals during the period of the mass vaccination program in South Korea (February to October 2021).ResultsWe identified 13 patients with GBS and variants post COVID-19 vaccination: AstraZeneca vaccine (Vaxzevria) in 8, and Pfizer-BioNTech vaccine (Comirnaty) in 5. The mean time interval from vaccination to symptom onset was 15.6 days (range 4–30 days). Electrodiagnostic classification was demyelinating in 7, axonal in 4 and normal in 2 cases. Clinical manifestations were diverse with varying severity: classical GBS in 8 cases, paraparetic variant in 3, Miller-Fisher syndrome in 1 and acute cervicobrachial weakness in 1. Four patients developed respiratory failure, and 2 of them showed treatment-related fluctuations.ConclusionOur observations suggest that COVID-19 vaccines may be associated with GBS of distinctive clinical features characterized by severe quadriplegia, disproportionately frequent bilateral facial palsy or atypical incomplete variants. Continuous surveillance and further studies using robust study designs are warranted to fully assess the significance of the association.

In these analyses, individuals vaccinated before the identified time duration considered unvaccinatedModel A: Adjusted for age, gender, place of residence;**Model B: Adjusted for Model A variables plus income, comorbidity, A(H1N1)pdm09 priority group, receiving the 2009/10 seasonal influenza vaccine, receiving a pneumococcal vaccine, immunosuppressed, pregnancy, ≥20 physician encounters in the last 5 years, ≥1 hospital admission in the last 5 years; use of antiviral prophylaxis and diagnosis of chronic renal failure.† Exact numbers between 1–5 are not reported as required by the data custodian to protect patient confidentiality.Estimates of the effectiveness (VE) of pandemic, seasonal influenza and pneumococcal vaccine against hospitalization with laboratory-confirmed influenza*.

Measles vaccine coverage before the outbreak in May 2011 and after the mass vaccination campaign in September 2013 and number of students vaccinated during the outbreak and during and after the vaccination campaign.

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data was reported at 77.600 % in 11 Apr 2022. This records an increase from the previous number of 73.900 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data is updated weekly, averaging 72.700 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 77.600 % in 11 Apr 2022 and a record low of 65.500 % in 03 Jan 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

Absolute increase in the school population immunity following the mass campaign by vaccination status before the campaign.

Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 99.000 % in 2016. This stayed constant from the previous number of 99.000 % for 2015. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 92.000 % from Dec 1982 (Median) to 2016, with 35 observations. The data reached an all-time high of 99.000 % in 2016 and a record low of 17.000 % in 1982. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Morocco – Table MA.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

Live Vaccines Market Outlook

The global live vaccines market size was valued at approximately USD 15 billion in 2023 and is projected to reach about USD 25 billion by 2032, growing at a robust CAGR of around 6%. The primary growth factor driving this market is the increasing incidence of infectious diseases and the subsequent need for effective immunization strategies. The proven efficacy of live vaccines in providing long-lasting immunity combined with technological advancements in vaccine delivery systems is fueling market expansion. Moreover, government initiatives for immunization programs, coupled with growing awareness about the benefits of vaccination, are further contributing to the market's impressive growth trajectory.

A significant driver of the live vaccines market is the rising awareness of the critical role vaccines play in preventing disease outbreaks. The COVID-19 pandemic significantly underscored the importance of vaccination, leading to increased investments in vaccine development and distribution. This heightened focus on vaccination has translated into increased demand for live vaccines, as they are known for their efficacy in generating robust and long-lasting immune responses. Additionally, advancements in biotechnology and genetic engineering have facilitated the development of more effective and safer live vaccines, thus enhancing their adoption globally.

The demand for live vaccines is further bolstered by the increased emphasis on childhood vaccination programs. With governments and international bodies, such as the World Health Organization, promoting widespread immunization to eradicate diseases like measles, mumps, and rubella, the market is witnessing a surge in demand for pediatric vaccines. Furthermore, the expansion of healthcare infrastructure in emerging economies is making vaccines more accessible to populations that previously had limited access, thereby driving market growth. As countries strive to achieve higher vaccination coverage, live vaccines, with their proven track record, are becoming an integral part of national immunization schedules.

Another growth factor is the continuous innovation in vaccine delivery methods, which has significantly improved the acceptance of live vaccines. Traditional injection methods are being supplemented with less invasive delivery systems, such as oral and intranasal routes, which are particularly useful in pediatric and mass vaccination programs. These innovations not only improve compliance but also enhance the overall effectiveness of vaccination campaigns. In addition, the integration of advanced technologies, such as micro-needles and nanoparticle delivery systems, is expected to drive the market further by making vaccines more efficient and easier to administer.

Regionally, North America currently dominates the live vaccines market, driven by the presence of leading pharmaceutical companies, high healthcare expenditure, and a well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, primarily due to the increasing investments in healthcare infrastructure, rising awareness about vaccination, and large populations in countries like China and India. Government initiatives focusing on immunization and the rising prevalence of infectious diseases in these regions are also contributing factors to the anticipated growth.

Vaccine Type Analysis

The live vaccines market is segmented by vaccine type into viral, bacterial, and combination vaccines. Viral vaccines dominate this segment due to their effectiveness in preventing viral diseases such as measles, mumps, rubella, and influenza. These vaccines work by introducing a weakened form of the virus to stimulate the body's immune response without causing the disease. Viral vaccines have a well-established safety profile, which has led to their widespread adoption in immunization programs worldwide. The ongoing research to develop vaccines for emerging viral infections, such as Zika and Ebola, is expected to further fuel the growth of this segment.

Bacterial vaccines, although smaller in market share compared to viral vaccines, play a crucial role in preventing bacterial infections like tuberculosis and typhoid. These vaccines contain live attenuated strains of bacteria and are known for their high efficacy in stimulating a strong immune response. The demand for bacterial vaccines is driven by the increasing prevalence of antibiotic-resistant bacterial strains, which has underscored the need for effective vaccination strategies. Continued research

BackgroundThe World Health Organization (WHO) recommends oral cholera vaccines (OCVs) as a supplementary tool to conventional prevention of cholera. Dukoral, a killed whole-cell two-dose OCV, was used in a mass vaccination campaign in 2009 in Zanzibar. Public and private costs of illness (COI) due to endemic cholera and costs of the mass vaccination campaign were estimated to assess the cost-effectiveness of OCV for this particular campaign from both the health care provider and the societal perspective. Methodology/Principal FindingsPublic and private COI were obtained from interviews with local experts, with patients from three outbreaks and from reports and record review. Cost data for the vaccination campaign were collected based on actual expenditure and planned budget data. A static cohort of 50,000 individuals was examined, including herd protection. Primary outcome measures were incremental cost-effectiveness ratios (ICER) per death, per case and per disability-adjusted life-year (DALY) averted. One-way sensitivity and threshold analyses were conducted. The ICER was evaluated with regard to WHO criteria for cost-effectiveness. Base-case ICERs were USD 750,000 per death averted, USD 6,000 per case averted and USD 30,000 per DALY averted, without differences between the health care provider and the societal perspective. Threshold analyses using Shanchol and assuming high incidence and case-fatality rate indicated that the purchase price per course would have to be as low as USD 1.2 to render the mass vaccination campaign cost-effective from a health care provider perspective (societal perspective: USD 1.3). Conclusions/SignificanceBased on empirical and site-specific cost and effectiveness data from Zanzibar, the 2009 mass vaccination campaign was cost-ineffective mainly due to the relatively high OCV purchase price and a relatively low incidence. However, mass vaccination campaigns in Zanzibar to control endemic cholera may meet criteria for cost-effectiveness under certain circumstances, especially in high-incidence areas and at OCV prices below USD 1.3.

BackgroundCanine transmitted rabies kills an estimated 59,000 people annually, despite proven methods for elimination through mass dog vaccination. Challenges in directing and monitoring numerous remote vaccination teams across large geographic areas remain a significant barrier to the up-scaling of focal vaccination programmes to sub-national and national level. Smartphone technology (mHealth) is increasingly being used to enhance the coordination and efficiency of public health initiatives in developing countries, however examples of successful scaling beyond pilot implementation are rare. This study describes a smartphone app and website platform, “Mission Rabies App”, used to co-ordinate rabies control activities at project sites in four continents to vaccinate over one million dogs.MethodsMission Rabies App made it possible to not only gather relevant campaign data from the field, but also to direct vaccination teams systematically in near real-time. The display of user-allocated boundaries on Google maps within data collection forms enabled a project manager to define each team’s region of work, assess their output and assign subsequent areas to progressively vaccinate across a geographic area. This ability to monitor work and react to a rapidly changing situation has the potential to improve efficiency and coverage achieved, compared to regular project management structures, as well as enhancing capacity for data review and analysis from remote areas. The ability to plot the location of every vaccine administered facilitated engagement with stakeholders through transparent reporting, and has the potential to motivate politicians to support such activities.ResultsSince the system launched in September 2014, over 1.5 million data entries have been made to record dog vaccinations, rabies education classes and field surveys in 16 countries. Use of the system has increased year-on-year with adoption for mass dog vaccination campaigns at the India state level in Goa and national level in Haiti.ConclusionsInnovative approaches to rapidly scale mass dog vaccination programmes in a sustained and systematic fashion are urgently needed to achieve the WHO, OIE and FAO goal to eliminate canine-transmitted human deaths by 2030. The Mission Rabies App is an mHealth innovation which greatly reduces the logistical and managerial barriers to implementing large scale rabies control activities. Free access to the platform aims to support pilot campaigns to better structure and report on proof-of-concept initiatives, clearly presenting outcomes and opportunities for expansion. The functionalities of the Mission Rabies App may also be beneficial to other infectious disease interventions.

United States SB: MA: COVID Test/Vaccine: Negative COVID Test: Yes data was reported at 5.900 % in 11 Apr 2022. This records a decrease from the previous number of 6.600 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: Yes data is updated weekly, averaging 8.750 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 18.400 % in 03 Jan 2022 and a record low of 3.500 % in 14 Mar 2022. United States SB: MA: COVID Test/Vaccine: Negative COVID Test: Yes data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

Vero Cell Rabies Vaccines for Human Market Outlook

The global market size for Vero Cell Rabies Vaccines for humans was valued at approximately USD 420 million in 2023 and is projected to reach USD 750 million by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This market growth is driven by factors such as the increasing incidence of rabies, growing awareness about rabies prevention, and the rising adoption of Vero cell technology in vaccine production. The advancements in biotechnology and the integration of innovative platforms for vaccine development are further enhancing the market's prospects.

One of the significant growth factors in the Vero Cell Rabies Vaccines market is the increasing incidence of rabies globally. Rabies remains a significant public health concern in many parts of the world, particularly in Asia and Africa, where the majority of rabies-related deaths occur. The World Health Organization (WHO) has emphasized the need for effective rabies control programs, which has subsequently increased the demand for effective and reliable vaccines. The use of Vero cells, which are derived from the kidney cells of African green monkeys, has proven to be effective in producing high-quality rabies vaccines, thereby driving market growth.

Another crucial factor contributing to the market's expansion is the growing awareness about rabies prevention and control. Governments, non-governmental organizations (NGOs), and health agencies are actively conducting awareness campaigns to educate the public about the importance of rabies vaccination. These initiatives aim to reduce the incidence of rabies by promoting pre-exposure prophylaxis for high-risk populations and post-exposure prophylaxis for those potentially exposed to the rabies virus. Such awareness programs are significantly boosting the demand for Vero cell rabies vaccines.

Technological advancements in vaccine production are also playing a pivotal role in the market's growth. The development of Vero cell technology has revolutionized the vaccine manufacturing process. This technology allows for the production of vaccines that are highly effective and have fewer side effects compared to traditional methods. Moreover, Vero cell-based vaccines are safer and more stable, making them suitable for mass immunization programs. The ongoing research and development in the field of biotechnology are expected to introduce innovative solutions, further driving the growth of the Vero Cell Rabies Vaccines market.

In the realm of rabies prevention, Antivenom plays a crucial role, especially when considering the broader spectrum of zoonotic diseases. While rabies vaccines are pivotal in preventing the onset of this deadly disease, antivenoms are essential in treating bites from venomous animals, which can often occur in the same regions where rabies is prevalent. The development and distribution of effective antivenoms are vital for comprehensive public health strategies in areas with high incidences of both rabies and venomous animal encounters. This dual approach ensures that communities are better protected against a range of animal-related health threats, thereby enhancing the overall effectiveness of rabies control programs.

From a regional perspective, the Asia Pacific region is expected to dominate the Vero Cell Rabies Vaccines market during the forecast period. This dominance is attributed to the high incidence of rabies in countries like India and China, where a significant portion of the global rabies burden is concentrated. Governments in these countries are implementing extensive vaccination programs to combat rabies, thereby increasing the demand for Vero cell rabies vaccines. Additionally, the growing healthcare infrastructure and increasing government expenditure on healthcare are further supporting market growth in this region.

Product Type Analysis

The Vero Cell Rabies Vaccines market is segmented by product type into Inactivated Vero Cell Rabies Vaccines and Live Attenuated Vero Cell Rabies Vaccines. Inactivated Vero Cell Rabies Vaccines hold a major share of the market due to their safety and efficacy. These vaccines are made by inactivating the virus, making them incapable of causing disease while still eliciting a strong immune response. The demand for inactivated vaccines is fueled by their established track record of safety, especially in immunocompromised individuals and children.

Live Attenua